Atypical cutaneous leishmaniasis in two patients receiving low-dose methotrexate.
Cutaneous leishmaniasis is a protozoan disease that has high morbidity. There have been increasing reports of leishmaniasis in patients with an underlying immunosuppressed state. We present two cases of cutaneous leishmaniasis caused by Old World species in patients on methotrexate therapy. We postulate that the T-cell-mediated response to leishmaniasis infection could be modulated by methotrexate and may render an immunosuppressed individual more susceptible to developing clinical disease.
Saha
M
M
Department of Dermatology, Bristol Royal Infirmary, Bristol, UK. monikasaha@doctors.net.uk
Shipley
D
D
McBride
S
S
Kennedy
C
C
Vega-Lopez
F
F
D000328:Adult; D000368:Aged; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016773:Leishmaniasis, Cutaneous / Q000276:immunology* / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D009894:Opportunistic Infections / Q000276:immunology* / Q000473:pathology
D007166:Immunosuppressive Agents; D008727:Methotrexate